← Leaderboards
Gregory A Cote
Indiana University Indianapolis
$4,527,547
Attributed
$11,409,245
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2011–25$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,409,245 · 6
By mechanism
U01$8,365,628 · 2
R01$1,411,157 · 1
K23$854,576 · 1
R21$427,270 · 1
U34$350,614 · 1
Top collaborators
- Peter B Cotton6 shared
- Lydia Foster6 shared
- Dhiraj Yadav6 shared
- Valerie L Durkalski5 shared
- Alexander Savio Ramos Guimaraes3 shared
- Rosalie C Sears3 shared
- Brett C Sheppard3 shared
Others in their field
Top investigators on “Enrollment”
- Jeffrey P Krischer · University Of South Florida$370,021,822
- Lawrence Corey · Fred Hutchinson Cancer Center$329,293,433
- David R. Weir · University Of Michigan At Ann Arbor$265,368,888
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$231,949,330
- James Dennis Neaton · Northwestern University$218,104,551
- George R Seage · Abt Associates, Inc.$205,403,788
Research focus
EnrollmentQuality Of LifeRandomizedEndoscopic Retrograde CholangiopancreatographyEtiologyPancreatic DuctBasePancreasHigh RiskClinical TrialsFollow-UpFuturePancreatitisProceduresInstrumentDiagnosisPerceived Quality Of LifeDiagnosticPrimary OutcomeRecurrenceSamplingBiliaryCohort StudiesIncidence
Grant awards (23)
Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs$766,920
U01 · FY2025 · CA
Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs$728,573
U01 · FY2024 · CA
Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs$766,920
U01 · FY2023 · CA
SpHincterotomy for Acute Recurrent Pancreatitis$1
U01 · FY2022 · DK · contact PI
SpHincterotomy for Acute Recurrent Pancreatitis$1,960,097
U01 · FY2021 · DK · contact PI
Results of Ercp in Sphincter of Oddi Dysfunction$225,441
R01 · FY2021 · DK · contact PI
SpHincterotomy for Acute Recurrent Pancreatitis$1,450,650
U01 · FY2020 · DK · contact PI
Results of Ercp in Sphincter of Oddi Dysfunction$276,798
R01 · FY2020 · DK · contact PI
Results of Ercp in Sphincter of Oddi Dysfunction$18,574
R01 · FY2020 · DK · contact PI
SpHincterotomy for Acute Recurrent Pancreatitis$1,399,189
U01 · FY2019 · DK · contact PI
Results of Ercp in Sphincter of Oddi Dysfunction$273,421
R01 · FY2019 · DK · contact PI
SpHincterotomy for Acute Recurrent Pancreatitis$1,293,278
U01 · FY2018 · DK · contact PI
Results of Ercp in Sphincter of Oddi Dysfunction$270,111
R01 · FY2018 · DK · contact PI
Results of Ercp in Sphincter of Oddi Dysfunction$346,812
R01 · FY2017 · DK · contact PI
Minor Endoscopic Sphincterotomy for Recurrent Acute Pancreatitis with Pancreas Divisum$350,614
U34 · FY2016 · DK · contact PI
Optimizing the role of ERCP in evaluating indeterminate bile duct strictures$169,759
K23 · FY2016 · DK · contact PI
Optimizing the role of ERCP in evaluating indeterminate bile duct strictures$171,143
K23 · FY2015 · DK · contact PI
Optimizing the role of ERCP in evaluating indeterminate bile duct strictures$126,148
K23 · FY2014 · DK · contact PI
Optimizing the role of ERCP in evaluating indeterminate bile duct strictures$42,049
K23 · FY2014 · DK · contact PI
Optimizing the role of ERCP in evaluating indeterminate bile duct strictures$169,158
K23 · FY2013 · DK · contact PI
Covered metal stents for treatment of post-liver transplant biliary strictures$194,895
R21 · FY2012 · DK · contact PI
Optimizing the role of ERCP in evaluating indeterminate bile duct strictures$176,319
K23 · FY2012 · DK · contact PI
Covered metal stents for treatment of post-liver transplant biliary strictures$232,375
R21 · FY2011 · DK · contact PI